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Context: The role and importance of circulating sclerostin is poorly understood. High Bone Mass
(HBM) caused by activating LRP5 mutations has been reported to be associated with increased
plasma sclerostin concentrations; whether the same applies to HBM due to other causes is
unknown.
Objective: To determine circulating sclerostin concentrations in HBM.
Design: Case-control study
Participants: 406 HBM index caseswere identified by screening DXA databases from 4UK centers
(n219,088), excluding significant osteoarthritis/artefact. Controls comprised unaffected rela-
tives & spouses.
Mainmeasure(s): Plasma sclerostin, lumbar spine L1, total hip and total body DXA, and radial and
tibial pQCT (subgroup only).
Results: Sclerostin concentrationswere significantly higher in both LRP5HBMand non-LRP5HBM
cases, compared with controls; mean[SD] 130.1[61.7] and 88.0[39.3], vs. 66.4[32.3]pmol/L, both
p<0.001, which persisted after adjustment for a priori confounders. In combined adjusted anal-
yses of cases and controls, sclerostin concentrations were positively related to all bone param-
eters found to be increased in HBM cases (i.e. L1, total hip and total body DXA BMD, and
radial/tibial cortical area, cortical BMD and trabecular density). Whilst these relationships were
broadly equivalent in HBM cases and controls, there was some evidence that associations
between sclerostin and trabecular phenotypes were stronger in HBM cases, particular for radial
trabecular density (interaction p<0.01).
Conclusions: Circulating plasma sclerostin concentrations are increased in both LRP5 and non-
LRP5 HBM compared with controls. In addition to the general positive relationship between
sclerostin and DXA/pQCT parameters, genetic factors predisposing to HBM may contribute to
increased sclerostin levels.
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Sclerostin is an endogenous, osteocyte-derived, solubleinhibitor of canonical wnt signaling and a potent in-
hibitor of osteoblastic bone formation. Despite associa-
tions with a range of factors, its role and importance is
poorly understood. In contrast protein function and ex-
pressionanalyseshaveadvancedunderstandingof scleros-
tin’s paracrine effects. However, while circulating scleros-
tin correlates with bone marrow plasma sclerostin, the
extent to which plasma sclerostin ‘leakage’ reflects under-
lying bone biology is unclear (1). Hence, studying plasma
sclerostin in a wide range of bone disorders is desirable.
Sclerostin concentrations are known to increase with age,
immobility, weight loss, the menopause, type II diabetes
mellitus, denosumab treatment, and are greater in men
than women (2–11). Estrogen replacement, PTH therapy
and physical activity, decrease sclerostin in postmeno-
pausalwomen (1, 3, 12),whilebisphosphonateshavevari-
able effects (7, 13, 14). Oral glucocorticoids decrease
sclerostin concentrations acutely, potentially through os-
teocyte apoptosis (15).
Sclerostin deficiency, occurring in Sclerosteosis
(OMIM 269500) and Van Buchem’s disease (OMIM
239100), leads towidespread increased bonemineral den-
sity (BMD) and a characteristic skeletal dysplasia includ-
ing fracture-resistance (16–18). Heterozygous carriers
have high bone mass (HBM), fracture resistance, but an
otherwise normal phenotype (19), hence current efforts to
develop sclerostin antibodies as a novel anabolic osteo-
porosis treatment. In rodents, in response to mechanical
loading (mechanotransduction), osteocytic sclerostin se-
cretion is reduced, alleviating inhibition of osteoblast ac-
tivity, increasing bone formation and BMD (20, 21);
raised sclerostin in response to immobility points towards
a similar effect in humans (8, 9, 11). However, the total
amount of bone may determine plasma sclerostin concen-
trations since, in the general population, sclerostin is pos-
itively related to total body BMD, particularly in older
individuals, and inversely related to bone turnover in men
and pre- and postmenopausal women (3, 4, 22). Recently
sclerostin has been positively associated with several mi-
croarchitectural parameters including trabecular density,
assessed by high resolution pQCT (23), and cortical
vBMD and area, by pQCT (24).
Elevated sclerostin concentrations have also been re-
ported in aHBM family with aT253Imutation in thewnt
pathway regulator low-density lipoprotein (LDL) recep-
tor-related protein 5 (LRP5) (25). While this may reflect
an effect of the mutation on sclerostin metabolism, asso-
ciations between bone mass, microarchitecture and
sclerostin may equally be responsible. Consistent with the
latter suggestion, pQCT analysis of a phenotypically sim-
ilar HBM population revealed differences in a number of
microarchitectural parameters, previously related to
sclerostin in the general population, including increased
trabecular density, cortical vBMD and area (23, 24, 26).
These potential relationships may be complicated further
as sclerostin has also been positively associated with fat
mass (27), as has HBM (28); hence sclerostin-bone rela-
tionships may be confounded by adiposity.
We planned to improve understanding of the relation-
ships between bone and circulating sclerostin by examin-
ing the rare and extreme HBM phenotype. We aimed to
determine whether (i) sclerostin concentrations are ele-
vated in HBM, then (ii) if any observed differences are
explained by LRP5 HBM mutations, and (iii) any differ-
ences reflect analtered relationshipbetween sclerostin and
bone parameters inHBM individuals, taking into account
established confounding factors.
Materials and Methods
Participant recruitment
The HBM study is a UK based multicenter observational
study of adults with unexplainedHBM.At 4 of our largest study
centers, 406HBM index cases were identified by screeningNHS
DXA databases (n 219,088), excluding scans with significant
osteoarthritis and/or other causes of raised BMD (eg, surgical
metalwork, Paget’s disease, metastases). Full details of DXA da-
tabase screening and participant recruitment have previously
been reported (29). In brief, HBM was defined as a) both L1
Z-score3.2 and total hip Z-score1.2 or b) both total hip
Z-score3.2 and L1 Z-score1.2. The L1 lumbar vertebra
was used as, in contrast to lower lumbar levels, it was not asso-
ciated with the presence of lumbar spine osteoarthritis assessed
on DXA images (29). Index cases passed on study invitations to
their first-degree relatives and spouse/partner(s). Relatives/
spouses with HBM in turn passed on invitations to their first-
degree relatives/spouses. HBM was defined among spouses as
per index cases, and among first-degree relatives as summed L1
Z plus total hip Z-score of3.2; reflecting an established fam-
ily history ofHBM. Family-based controls comprised unaffected
relatives and spouses. All participants were clinically assessed by
one doctor using a standardized structured history and exami-
nation questionnaire, after which total body (TB) DXA scans
and (nonfasted) phlebotomy were performed. None had a his-
tory of parathyroid disease.
Subsequently, current and life-time physical activity (PA)was
measured by short (10-minute) postal questionnaire (prepaid
reply envelope, sent up to 3 times) which included (i) the short
last 7 days self-administered International PA Questionnaire
(IPAQ 2002, http://www.ipaq.ki.se/ipaq.htm(30, 31) and (ii) a
historical PA questionnaire (32–34). 86.5% completed PA ques-
tionnaires: those who did not respond had similar anthropomet-
ric characteristics to those who did (data not shown).
Recruitment ran from September 2008 until April 2010.
Written informed consent was collected for all in line with the
Declaration of Helsinki (35). Participants were excluded if
aged 18, pregnant or unable to provide written informed con-
sent for any reason. This study was approved by the Bath Mul-
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ticenter Research Ethics Committee (REC) and at each NHS
Local REC.
Sclerostin and bone turnover markers
Two nonfasted EDTA samples were collected and plasma
separated and frozen within 4 hours to –80°C. Sclerostin con-
centrations were measured using ELISA immunoassay (BI-
20442, Biomedica, Vienna, Austria) (detection limit 3.6 pmol/L)
(standard range 0–80 pmol/L). Bone formation (Procollagen
type 1 amino-terminal propeptide[PINP], total osteocalcin) and
resorption (-C-telopeptides of type I collagen[CTX]) markers
were also measured. All had interand intra-assay coefficients of
variation  6.0% across the assay working ranges. Electro-
chemiluminescence immunoassays (ECLIA) (Roche Diagnos-
tics, Lewes, UK) were used to measure plasma concentrations of
PINP, osteocalcin, andCTX (detection limits 4.0, 0.6, 0.01g/L
respectively).
DXA measurements
DXA scans were performed using either GE Lunar Prodigy
DXA (software v.13.2, GE Healthcare, Madison, WI, USA) in
Birmingham, Cambridge and Hull, or Hologic Discovery/W
DXA (software version Apex 3.0, Hologic Inc. Bedford, MA,
USA) in Sheffield. All scans were acquired and analyzed accord-
ing to each manufacturer’s standard scanning and positioning
protocols. TBBMDandFatMass (FM)weremeasured, together
with L1 and total hip BMD. Known differences in calibration
exist between Hologic and GE for all scan type (36, 37). For
lumbar spine and hip scans, systematic bias was limited by con-
verting all measures to standardized BMD (sBMD) (38, 39). For
TB, systematic differences were limited using cross-calibration
equations for all bone and soft tissue regions of interest (37, 40).
Full details have previously been reported, including quality con-
trol (QC) checks and grading of TB scans for metallic artifact
(28). Since only 330 (59.5%) of the original multicenter study
population (29) had TB DXA scans performed, the principle
characteristics of individuals who received a TB DXA scan were
compared to thosewho did not. No differences were observed in
weight, height, sex, age, or ethnicity (data not shown).
Peripheral Quantitative Computed Tomography
(pQCT) measurements
At are our largest study center, having the necessary equip-
ment, pQCT scanning was performed at the distal and midshaft
of the tibia (4&66%fromdistal endplate) and radius (4&60%)
in nondominant lower and upper limbs respectively, using a
StratecXCT2000L (StratecMedizintechnik, Pforzheim,Germa-
ny); voxel size 0.5mm,CTspeed30mm/s,XCTsoftware version
5.50d; details previously described in full (26). Initial frontal
scout view determined a distal endplate reference line. Cortical
bone was defined using a threshold 650 mg/cm3 (optimal for
bone geometry (41)). Trabecular bone was identified by elimi-
nation of cortical bone and therefore trabecular density was de-
fined as  650 mg/cm3. Cortical parameters were measured:
cortical BMD, total bone area(BA) (ie, total bone cross-section,
reflecting periosteal expansion), cortical BA (reflecting com-
bined periosteal and endosteal expansion). Strength Strain Index
(SSI) was calculated according to Stratec’s manual
(SSISM*(cBMD[mg/cm3]/1200[mg/cm3]), where 1200 mg/
cm3 represents normal bone physiological density and SM (Sec-
tion Modulus)CSMI/periosteal radius, where CSMI (Cross-
Sectional Moment of Inertia[cm4)])(periosteal radius4-
endosteal radius4)/4) (42).
Statistical methods
Descriptive statistics are presented as mean (95% confidence
interval (CI)[CI]) for continuous and count (percentages) for
categorical data. Analyses comparing two continuous variables
are presented as  coefficients and 95%CIs for standardized
outcomes. Linear regression was used to analyze continuous
variables, using random effects models to allow for the lack of
statistical independence due to within-family clustering of envi-
ronmental factors and shared genotypes. Age, gender, historical/
current PA, height, TB FM, menopausal status and estrogen re-
placement therapy in women (an established regulator of
sclerostin (12)), were considered a priori confounders of asso-
ciations between HBM status and sclerostin, DXA and bone
turnover parameters.
Further potential confounders included: history of malig-
nancy, diabetes mellitus, glucocorticoid (current/previous/never
use), antiresorptive medication use (7, 13–15). Bone density and
microarchitecture analyses were stratified to assess interactions
by HBM case/control status. Data were managed using Mi-
crosoft Access (data entry checks; error rate  0.12%) and an-
alyzedusingStata release12 statistical software (StataCorp,Col-
lege Station, TX, USA).
Results
Participant characteristics
In total 202 HBM cases (151 index cases, 49 affected
relatives, 2 affected spouses) and 123 family controls (87
unaffected relatives, 36unaffected spouses)were assessed.
HBMcases (age range26–90years)wereolder than family
controls (19–88years), more commonly female, post-
menopausal and had used estrogen replacement (Table 1).
Only four HBM cases were not of white European origin.
Plasma sclerostin concentrations
As expected, sclerostin concentrations were strongly
associated with age in both HBM cases (unadjusted stan-
dardized  per year increase in age 0.03 [0.02,0.04], P 
.001) and controls (0.02 [0.01,0.03],P .001) to a similar
degree (interaction P  .48). Sclerostin concentrations
(mean [SD]) were higher in males than females in both
HBM cases (112.5 [46.8] vs. 80.9 [33.7]pmol/L, P 
.001)) and controls (72.8 [37.2] vs. 58.6 [23.1]pmol/L,
P .042), without evidence of interaction. Sclerostin con-
centrations were independent of bone turnover markers
(overall and inmen,women,HBMcases and controls) and
TB FM (data not shown).
Unadjusted sclerostin concentrations were signifi-
cantly higher among HBM cases compared with controls
(Table 2). These differences were maintained after adjust-
ment for a priori confounders, ie, age, gender, historical/
current PA, height, TB FM, and in women years since
doi: 10.1210/jc.2013-3958 jcem.endojournals.org 3
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 21 May 2014. at 08:40 For personal use only. No other uses without permission. . All rights reserved.
menopause and estrogen replacement therapy. Additional
adjustment for diabetes mellitus, malignancy, glucocorti-
coid andantiresorptive usedidnot influence these findings
(Supplementary Table 1).
To determine the impact of rare cases of HBM caused
by anabolic mutations in LRP5, identified by previous
Sanger sequencing (43), we firstly assessed sclerostin con-
centrations in 6 cases of LRP5HBM, and secondly in the
196 non-LRP5 HBM cases. Sclerostin concentrations
were highest among the 6 LRP5 HBM cases (mean[SD],
130.1[62.7]pmol/L)(Figure 1), but were also elevated in
non-LRP5 HBM cases compared with controls (unad-
justed mean difference 22.1 [13.3,30.9]pmol/L, P 
.001)(Figure 1). Adjustment for a priori confounders did
not diminish the difference in sclerostin concentrations
observed between non-LRP5 HBM cases and controls
(Figure1).Theapriori adjustedmeandifference in scleros-
tin levels between LRP5 and non-LRP5 HBM cases was
halved by further adjustment for TB BMD (mean differ-
ence 35.2 [-0.92,71.3]pmol/L, P  .056).
Sclerostin and DXA measured BMD
As previously reported (29), BMD was considerably
higher in HBM individuals than controls in unadjusted
analyses, and persisted after adjustment for a priori and
additional confounders (Table 2, SupplementaryTable 1).
To establish whether sclerostin differences could be ex-
plained by variation in BMD, we firstly investigated the
relationship between DXA BMD and sclerostin in our
combined study population. Before adjustment, strong
positive relationships were seen between BMD and
sclerostin ( represents SD change in sclerostin per SD
increase in BMD) measured at L1 (0.32 [0.22,0.43]), the
total hip (0.25 [0.15,0.35]) andTB (0.26 [0.16,0.37]),P
.001 for all. Equivalent relationships were observed after
adjustment for a priori confounders (Table 3), and addi-
tional confounders (Supplementary Table 2). In further
analyses, intended to examine whether BMD-sclerostin
relationships differed according to HBM case status, as-
sociations were generally stronger between DXA BMD
parameters and sclerostin in HBM cases, as judged by 
coefficients, especially for L1 BMD; however, despite this
no formal HBM case-control interactions were detected
(all P  .05)(Table 3).
Sclerostin and bone microarchitecture measured
by pQCT
The positive relationships observed between DXA
measured BMD and sclerostin were next investigated us-
ing lower and upper limb pQCT available in 95 HBM
Table 1. Clinical characteristics of High Bone Mass cases and family controls
HBM Cases
(n  202)
Controls
(n  123)
p
valuea
Mean (SD) Mean (SD)
Age (years) 61.4 (13.6) 55.2 (16.3) 0.001
Height (cm) 166.6 (9.2) 171.6 (10.6) 0.001
Weight (kg) 85.3 (17.4) 84.0 (17.4) 0.784
BMI (kg/m2) 30.7 (5.8) 28.4 (5.0) 0.001
TB LM (kg) 46.8 (10.2) 51.5 (11.3) 0.001
TB FM (kg) 35.7 (12.5) 30.0 (11.3) 0.001
n (%) n (%)
Female 153 (76.5) 55 (44.7) 0.001
Postmenopausal 127 (83.0) 29 (52.7) 0.001
Estrogen
replacement use (ever)
77 (53.1) 9 (18.4) 0.001
Previous fracture (ever) 75 (37.5) 61 (49.6) 0.033
Diabetes mellitus 20 (10.0) 10 (8.1) 0.574
Current/previous
glucocorticoid use
49 (24.5) 19 (15.5) 0.053
Malignancy (ever) 31 (15.5) 7 (5.7) 0.008
Current PA (IPAQ) (n 
290)
Low 28 (15.4) 14 (13.0)
Moderate 71 (39.0) 41 (38.0) 0.791
High 83 (45.6) 53 (49.1)
Historical PA score (n 
288)
Very low (0–4) 21 (11.7) 13 (12.0)
Low (5–7) 34 (18.9) 27 (25.0)
Moderate (8–10) 37 (20.6) 26 (24.1) 0.369
High (11–14) 45 (25.0) 17 (15.7)
Very high (15–24) 43 (23.9) 25 (23.2)
HBM: High Bone Mass. SD: Standard Deviation. BMI: Body Mass Index. TB: Total Body. FM: Fat Mass, LM: Lean Mass. PA: Physical Activity. IPAQ:
International Physical Activity Questionnaire.
a Unadjusted p value from regression model accounting for within family clustering Only 9 HBM cases and 2 controls had ever used anti-resorptive
medication.
No individuals had hypercalcaemia.
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cases and65 controls (4 tibial pQCT images discardeddue
tomovement artifact).When the clinical characteristics of
individuals undergoing pQCT assessment were compared
to those who did not, no differences were observed in
gender, age, weight, height, physical activity, menopausal
status or estrogen replacement use (data not shown). Be-
fore adjustment, trabecular density was markedly greater
at both the tibia and radius, in HBM cases compared with
controls, as were cortical density and thickness, albeit to
a lesser extent (Table 2). After adjustment for a priori
confounders, trabecular density, cortical density, cortical
BA, and SSI, at both the tibia and radius,were all observed
to be greater in HBM cases compared with controls; how-
ever, bone sizes (total BA) were similar (Table 2). Equiv-
alent resultswere obtained after adjustment for additional
confounders (Supplementary Table 1).
Using our regression model adjusted for a priori con-
foundersweassessed the strengthof relationshipsbetween
SD changes in our pQCT measures of bone microarchi-
tecture and sclerostin (standardized). In the study popu-
lation as a whole, at both the radius and tibia, strong
positive relationships were seen between trabecular den-
sity, cortical density, cortical BA and sclerostin; a rela-
tionship with SSI was only seen at the radius. Sclerostin
was independent of bone size (total BA) in both upper and
lower limbs (Table 3). These relationships were un-
changedby further adjustment for PINP, plasmaCTXand
osteocalcin (data not shown), or by further potential con-
founders (diabetes mellitus, malignancy, glucocorticoid
and antiresorptive use)(Supplementary Table 2). In strat-
ified analyses, few consistent differences were observed in
the relationships between pQCT parameters and scleros-
tin in HBM cases and controls. The main exception was
the association between trabecular density and sclerostin,
whichwas stronger inHBMcases compared to controls at
both the radius and tibia,with a formal interaction by case
status observed in the upper limb (Table 3, Figure 2).
Sensitivity analyses
Relationships between measured (DXA and pQCT)
boneparameters and sclerostinwerenotmaterially altered
Table 2. DXA and pQCT measurements in High Bone Mass cases compared with family controls
n  323
HBM mean
(SD)
Control
mean
(SD)
Unadjusted
Mean
difference
(95%CI)
Un-adjusted
p value
Adjusteda
Mean
difference
(95%CI)
Adjusted p
valuea
Sclerostinb
(pmol/liter)
89.6 (40.7)c 66.4 (32.3) 21.9 (13.6,
30.1)
0.001 23.5 (14.5,
32.4)
0.001
DXA
L1 sBMD
(g/cm2)
1.40 (0.16) 1.08 (0.16) 0.32 (0.29,
0.36)
0.001 0.35 (0.32,
0.39)
0.001
Total Hip
sBMD (g/cm2)
1.25 (0.18) 0.99 (0.14) 0.25 (0.21,
0.28)
0.001 0.29 (0.25,
0.32)
0.001
TB BMD
(g/cm2)d
1.34 (0.13) 1.22 (0.12) 0.11 (0.09,
0.14)
0.001 0.16 (0.13,
0.18)
0.001
Tibia pQCT
(n  156)
Total BA
(mm2)
633.5 (98.4) 653.3 (111.0) 20.3 (-53.4,
12.8)
0.229 21.5 (-7.33,
50.3)
0.144
Cortical BMD
(mg/cm3)
1127.7 (33.2) 1111.4 (51.9) 16.2 (2.85,
29.6)
0.017 18.5 (3.44,
33.6)
0.016
Cortical BA
(mm2)
337.6 (55.3) 325.2 (67.6) 12.4 (-6.95,
31.7)
0.209 33.4 (20.3,
46.4)
0.001
SSI (mm3) 1651.0
(363.1)
1636.3
(435.7)
14.8 (-111.1,
140.6)
0.818 191.7 (110.7,
272.7)
0.001
Trabecular
BMD
(mg/cm3)
315.2 (34.0) 276.6 (38.5) 38.6 (27.3,
50.0)
0.001 40.5 (28.8,
52.3)
0.001
Radius pQCT
(n  160)
Total BA
(mm2)
161.1 (32.5) 161.8 (29.7) 1.1 (-10.8,
8.57)
0.823 7.63 (-1.43,
16.7)
0.099
Cortical BMD
(mg/cm3)
1170.0 (38.1) 1151.2 (60.4) 18.8 (3.52,
34.0)
0.016 27.1 (10.8,
43.5)
0.001
Cortical BA
(mm2)
99.8 (16.7) 96.7 (20.4) 3.10 (-2.68,
8.88)
0.293 12.1 (7.32,
16.8)
0.001
SSI (mm3) 241.1 (63.3) 233.7 (65.9) 7.43 (-12.9,
27.7)
0.473 34.7 (17.6,
51.8)
0.001
Trabecular
BMD
(mg/cm3)
286.9 (34.5) 264.0 (33.9) 22.9 (12.2,
33.7)
0.001 26.7 (14.7,
38.6)
0.001
HBM: High Bone Mass (excluding LRP5 HBM), DXA: Dual x-ray Absorptiometry. L1: 1st lumbar vertebra, BMD: Bone Mineral Density, sBMD:
standardised BMD, CI: Confidence Interval, BA: Bone area. All pQCT measures taken from the 66% or 60% slices for tibia and radius respectively,
except for trabecular density measured at the 4% slice. aadjusted for age, gender, historical and current physical activity, height, TB FM, years
since menopause and estrogen replacement therapy in women, p values from regression accounting for within family clustering. bstandard range
0–80pmol/liter. Unadjusted median[IQR] for HBM cases and controls: 81.1[61.6,103] & 60.4[43.7,86]pmol/liter respectively). c145 HBM cases with
L1 Z-score 3.2 mean [SD] sclerostin 91.1 [40.7]. 87 HBM cases with total hip Z-score 3.2 with sclerostin 94.4 [38.2]. 65 HBM cases with
both L1 Z-score 3.2 & total hip Z-score 3.2 with sclerostin level of 95.2 [41.6]. dadjusted for metallic artefact.
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after exclusion of LRP5 HBM cases (Supplementary Ta-
bles 3, 4, 5, 6 & 7).
Discussion
This study is the first to measure circulating sclerostin
concentrations ina largepopulationwithHBM.We found
HBM cases, identified by screening routine NHS DXA
databases across the UK, to have substantially increased
sclerostin concentrations in comparison to their unaf-
fected family members. Sclerostin concentrations in most
of ourLRP5HBMcases, previously identifiedby capillary
sequencingof exons2, 3 and4 (43),were higher compared
not only to controls, but to the remainder of the HBM
population. Our findings are consistent with the one
LRP5 HBM family pedigree in which sclerostin has been
measured; although the specific mutation differed from
ours, average sclerostin concentrations were almost dou-
ble that of controls, just as we observed (25). Even after
excluding individuals with LRP5 mutations, sclerostin
concentrationswere significantlyhigher inourHBMcases
than among controls; a difference unchanged by adjust-
ment for factors we confirmed influence sclerostin con-
centrations, such as age and gender.
The higher sclerostin concentrations among our HBM
cases are likely to be, at least partly, explained by the
positive relationship between sclerostin and BMD. This
relationship, previously reported in population-based
studies of lumbar and total hip BMD (4, 13, 22), was also
seen here at L1, total hip and total body BMD among
pooled HBM cases and controls. This may reflect an as-
sociation between sclerostin and total osteocyte number,
given that osteocytes are a major source of sclerostin (44,
45), andBMDreflects theamountofbone tissueandhence
osteocyte number. Our microarchitectural analyses sup-
port elevated sclerostin concentrations reflecting a greater
quantity of bone tissue in HBM cases. As previously re-
ported (26), pQCT analyses revealed HBM cases to have
greater cortical and trabecular bone, demonstrated by in-
creased cortical area and trabecular density respectively,
bothofwhich showedpositive associationswith sclerostin
in pooled analyses ofHBMcases and controls. These find-
ings concur with recent population-based analyses in
which sclerostin has been positively related to cortical
bone area and trabecular density in olderwomen (24), and
cortical thickness and trabeculardensity inadultmen (23).
We identified a positive relationship between sclerostin
and cortical BMD, as observed in population-based stud-
ies (23, 24); this may contribute to the increased sclerostin
in HBM cases, since cortical BMD is also raised in HBM.
Dense cortical bone, with fewer remodeling spaces, may
consequently harbor more osteocytes resulting in greater
sclerostin production. However, greater cortical BMD
may result in greater measured cortical thickness by re-
ducing the impact of partial volume effects which other-
wise limit edge detection accuracy in the presence of low
cortical BMD. Alternatively, since cortical BMD is in-
versely related to bone remodeling and turnover, the pos-
itive relation between sclerostin and cortical BMD, which
we and others have observed, may reflect an inverse as-
sociation between bone turnover and plasma sclerostin.
Such a relationship has previously been suggested in post-
menopausal women and older men (3, 22) although po-
tentially not for osteocalcin (12), although in the present
studynoassociationwasobservedbetween sclerostin con-
centrations and bone turnover, despite the validity of our
sclerostin assay (46). The clinical utility of sclerostin mea-
surement remains to be determined.
Although sclerostin concentrations were elevated in
HBM cases both with and without LRP5mutations, they
were highest in most with LRP5 mutations compared to
other HBM cases. This may reflect a more extreme phe-
notype in LRP5HBM, with greater amounts of bone tis-
sue (reflected by greater trabecular and cortical bone vol-
umes (26)) and hence osteocyte number, than occurs in
non-LRP5 HBM cases. Consistent with this suggestion,
Figure 1. Plasma sclerostin concentrations in HBM cases
with and without LRP5 anabolic mutations and controls.
LRP5 HBM cases n  6. Non-LRP5 HBM cases n  196. Controls n 
123. **P  .001. Unadjusted mean difference between LRP5 HBM
cases and controls  63.4 [35.4,91.5]**, between non-LRP5 HBM
cases and controls  22.1 [13.3,30.9]**, and between LRP5 HBM
cases and non-LRP5 HBM cases  42.0 [9.32,74.8], P  .012. Figure
shows mean differences in sclerostin shown with 95% confidence
intervals after adjustment for a priori confounders (age, gender,
historical and current physical activity, height, TB FM, years since
menopause and estrogen replacement therapy in women). The
unadjusted data points for the n  6 LRP5 HBM cases are
superimposed in gray rectangles.
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Table 3. Adjusted regression coefficients for associations between sclerostin and standardized bone parameters
DXA BMD (n 
320)  (95% CI)b
P
valueb
P
valuec
L1 sBMD (g/cm2) All 0.290 (0.185,
0.395)
0.001 0.167
HBM 0.313 (0.087,
0.539)
0.007
Controls 0.051 (-0.129,
0.231)
0.580
Total Hip sBMD
(g/cm2)
All 0.339 (0.203,
0.448)
0.001 0.402
HBM 0.341 (0.129,
0.554)
0.002
Controls 0.127 (-0.104,
0.358)
0.283
TB BMD (g/cm2)a All 0.344 (0.223,
0.465)
0.001 0.464
HBM 0.310 (0.093,
0.528)
0.005
Controls 0.156 (-0.044,
0.356)
0.126
TIBIA pQCT (n 
156)
Total BA (mm2) All 0.029 (-0.214,
0.272)
0.818 0.213
HBM 0.042 (-0.323,
0.408)
0.821
Controls 0.180 (-0.510,
0.150)
0.286
Cortical BMD
(mg/cm3)
All 0.182 (0.018,
0.346)
0.029 0.191
HBM 0.061 (-0.222,
0.344)
0.673
Controls 0.291 (0.083,
0.499)
0.006
Cortical BA
(mm2)
All 0.451 (0.171,
0.730)
0.002 0.325
HBM 0.268 (-0.208,
0.744)
0.270
Controls 0.526 (0.107,
0.944)
0.014
SSI (mm3) All 0.323 (0.043,
0.602)
0.024 0.367
HBM 0.172 (-0.295,
0.638)
0.471
Controls 0.232 (-0.195,
0.659)
0.287
Trabecular BMD
(mg/cm3)
All 0.307 (0.147,
0.468)
0.001 0.301
HBM 0.298 (0.032,
0.564)
0.028
Controls 0.113 (-0.163,
0.388)
0.422
RADIUS pQCT (n
 160)
Total BA (mm2) All 0.060 (-0.224,
0.104)
0.476 0.140
HBM 0.081 (-0.305,
0.143)
0.478
Controls 0.098 (-0.359,
0.163)
0.462
Cortical BMD
(mg/cm3)
All 0.252 (0.101,
0.402)
0.001 0.699
HBM 0.239 (-0.027,
0.504)
0.078
Controls 0.106 (-0.098,
0.310)
0.309
Cortical BA
(mm2)
All 0.254 (0.067,
0.441)
0.008 0.363
HBM 0.147 (-0.156,
0.449)
0.342
Controls 0.170 (-0.093,
0.432)
0.204
SSI (mm3) All 0.119 (-0.067,
0.305)
0.211 0.303
HBM 0.043 (-0.229,
0.315)
0.756
Controls 0.037 (-0.245,
0.318)
0.799
Trabecular BMD
(mg/cm3)
All 0.382 (0.228,
0.537)
0.001 0.009
HBM 0.499 (0.264,
0.735)
0.001
Controls 0.137 (-0.068,
0.342)
0.190
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LRP5 HBM cases had greater BMD compared to the re-
mainder of the HBM population (our unpublished obser-
vations); LRP5HBMmice models exhibit reduced osteo-
cyte apoptosis (47). Alternatively, individuals with LRP5
mutations may produce greater amounts of sclerostin for
a given quantity of bone tissue, compared to non-LRP5
HBMcases.While the small numbers ofLRP5HBMcases
limited our ability to examine this question, we found
some evidence that HBM cases overall produce relatively
large amounts of sclerostin per unit of bone tissue, as re-
flected by the stronger relationship particularly between
radial trabecular density and sclerostin concentrations in
HBM cases, than was seen in controls. If HBM cases have
predisposing genetic factors towards greater BMD and
greater sclerostin concentrations, these effects may be ex-
aggerated in those harboring LRP5mutations. For exam-
ple, rare monogenic LRP5 HBM cases are likely to have
mutations conveying a relatively strong functional effect,
compared with that of common polymorphisms affecting
BMD. Polymorphisms in established BMD genes are
known to be over-represented among individuals with
HBM (48–50), suggesting common polymorphisms, each
individually exerting relatively weak effects, contribute to
the extremebonephenotype inournon-LRP5HBMcases.
Any tendency for sclerostin production to be preferen-
tially increased in LRP5 HBM may reflect which molec-
ular pathway(s) have been perturbated. LRP5, a cell sur-
face coreceptor regulating canonical wnt signaling, plays
a central role in osteoblast differentiation (51). Anabolic
LRP5 mutations disrupt binding of endogenous wnt in-
hibitors such as dickkopf1, prompting activation of
down-stream signaling and gene transcription via
-catenin. Expression of sclerostin, which also functions
as an endogenous inhibitor ofwnt signaling,may conceiv-
ably be increased in this context of dysregulated activation
of wnt signaling. Potentially a subset of non-LRP5HBM
cases may also arise from genetic perturbations affecting
wnt signaling, which might contribute to the increased
HBM: High Bone Mass (excluding LRP5 HBM). L1: 1st lumbar vertebra. sBMD: standardised Bone Mineral Density. TB: Total Body. BA: Bone Area.
SSI: Strength Strain Index. All pQCT measures taken from the 66% or 60% slices for tibia and radius respectively, except for trabecular density
measured at the 4% slice (95 HBM cases, 65 controls).
 represents SD change in sclerostin per SD increase in BMD/Bone parameter. a Adjusted for metal artefact. b Adjusted for age, gender, historical
and current physical activity, height, TB FM, years since menopause and estrogen replacement therapy in women. c Interaction p value.
Figure 2. Plasma sclerostin concentrations vs. trabecular density measured by pQCT at the distal radius and tibia. HBM:
High Bone Mass cases (not explained by LRP5 mutations), black circles, FC: Family Controls; gray triangles.  represents SD change in sclerostin per
SD increase in trabecular density, with 95% CI shown. aAdjusted for age, gender, historical and current physical activity, height, TB FM, years since
menopause and estrogen replacement therapy in women.
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sclerostin concentrations observed in our analyses. Inter-
estingly, of the common polymorphisms associated with
BMD in large scale genome-wide association studies, gene
ontology links several to roles inosteoblasticwnt signaling
(49, 52); as discussed above, polymorphisms in these
BMD-associated loci occur more frequently in our HBM
population.
Importantly, sclerostin is not osteocyte specific; a range
of isoforms have been localized in osteoblasts, osteoclasts
and chondrocytes (53). In rodent models sclerostin is
strongly expressed in ossified ligaments and osteophytes
emerging by endochondral ossification (54). HBM has
been associated with both ligament ossification, and in-
creasedprevalence of joint replacement (potentially due to
osteoarthritis) (29, 55) andmore recently genetic markers
forMEF2C and SOX6,which both have regulatory roles
in endochondral ossification (48, 49).
Limitations
One potential limitation concerns control individuals
who comprised relative/spouses rather than being drawn
from the general population. These were considered suit-
able as (i) they had appropriate BMD (Table 1), (ii) they
share common environmental factors with cases which
would otherwise be difficult tomeasure and control for as
confounding factors, (iii) their inclusion aids future ge-
netic analyses as trait-associated haplotypes can be readily
identified. However, family controls are likely to have
been more similar to HBM cases than unrelated popula-
tion controls; hence clustered analyses were performed to
account for the lack of statistical independence due to
within-family clustering of environmental factors and
shared genotypes. Despite this, our reported differences
may still underestimate the true magnitude of the HBM
phenotype, than hadHBMcases been comparedwith gen-
eral population controls. We were able to adjust for dif-
ferences between cases and controls in gender, postmeno-
pausal status, estrogen replacement, glucocorticoid use
and prior history of malignancy which reflect referral in-
dications for clinicalDXAservices (29).However,we can-
not exclude residual confounding, for example by PTHor
renal function; measurements we lacked. Reduced sample
size limited analysis of pQCT measurements which were
only available in 50%; however, these individuals were
representative of the whole study population.
Conclusions
Our case-control study found plasma sclerostin concen-
trations to be increased inHBM cases compared to family
controls. These increases were particularly marked in
HBMcaseswithLRP5mutations, although caseswithout
LRP5mutations also hadhigher sclerostin concentrations
compared to controls. Sclerostin was positively related to
BMD, measured by DXA, and to trabecular density and
cortical area, measured by pQCT, all of which were mea-
sures foundalso tobe increased inHBM.Hence, sclerostin
concentrations may be increased in HBM in part due to a
greater osteocyte number resulting fromgreater quantities
of trabecular and cortical bone tissue. In addition, greater
production of sclerostin per unit of bone tissue may con-
tribute to these differences, as suggested by the stronger
relationship between sclerostin concentrations and tra-
becular density in HBM cases compared to controls. Fur-
ther analyses of relationships between sclerostin and ge-
netic factors predisposing toHBM is justified, to shed new
light on the mechanisms regulating sclerostin production.
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